Live News ›

India Pharma Faces Supply Woes Despite Duty Waivers

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
India Pharma Faces Supply Woes Despite Duty Waivers
Overview

India's pharmaceutical sector continues to face supply chain risks for vital petrochemical inputs, despite the government waiving customs duties on over 40 products until June 30. Industry executives emphasize that securing timely shipments, not just lower costs, is the main challenge. Saudi chemical giant SABIC’s force majeure declaration on key materials highlights these supply concerns amid rising global volatility.

Supply Chain Vulnerability

Ensuring a steady supply of petrochemical inputs is the top priority for India's pharmaceutical sector, especially with the conflict in West Asia. While the government's temporary customs duty waiver on over 40 critical products helps reduce costs, the main issue is still getting these essential materials physically and moving them on time.

Geopolitical Headwinds

Disruptions to key shipping routes like the Strait of Hormuz and the Red Sea have made supply chains more vulnerable. Saudi chemical giant SABIC's force majeure declaration on methanol and styrene highlights the seriousness of the situation. Many ships are now taking longer routes around the Cape of Good Hope, adding weeks to delivery times and putting pressure on the stock levels manufacturers depend on.

Government Support and Export Boost

The recent duty waiver, covering items such as anhydrous ammonia, methanol, styrene, and various polymers until June 30, aims to ease the impact of rising prices. Industry groups, like the Pharmaceuticals Export Promotion Council of India (Pharmexcil), welcome the relief but note its real benefit depends on stable global prices for these goods. Separately, the RoDTEP scheme has been reinstated to its earlier levels, which should help Indian medical device and pharmaceutical exporters compete better worldwide.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.